Is liposomal iron superior in treating anemic children with congenital acyanotic heart diseases? A randomized controlled clinical trial
Open Access
- 14 October 2026
- journal article
- research article
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 131
Abstract
Background: Children with congenital heart disease (CHD) often suffer from Iron deficiency anemia (IDA), which is linked to poorer clinical outcomes. Liposomal iron has been proposed as a promising advancement in iron supplementation across diverse populations. This study compared the efficacy as measured by changes in hemoglobin from baseline to end of study, and the tolerability of liposomal and conventional iron, with an emphasis on some clinical outcomes. Methods: A randomized, double-blind, controlled clinical trial was conducted at Cairo University Children’s Hospital (CUCH). Sixty-seven children aged 6 months to 12 years with clinically stable children with hemodynamically insignificant acyanotic congenital heart disease (ACHD) and mild-to-moderate IDA were included. Patients were randomly assigned to one of the treatment regimens: oral iron hydroxide polymaltose complex (3 mg/kg/day) or oral liposomal iron (1 mg/kg/day) for four weeks. A nutritional assessment was performed, and hematological and iron indices were evaluated. Results: After four weeks of iron supplementation, the percentage changes in Hb ( p = 0.137) and other hematological and iron indices did not differ between the two intervention groups, except for greater improvement in anemia severity grading in the liposomal iron group ( p = 0.05). A lower incidence of constipation ( p = 0.015) and metallic taste ( p = 0.007) was reported in the liposomal iron group. Conclusions: No significant difference was observed between the two treatment groups in Hb levels and other hematological and iron indices after four weeks of treatment. However, fewer adverse effects were reported in the liposomal iron group. Registry: PACTR, TRN: PACTR202501496307274, and date of registration: January 23, 2025.Keywords
This publication has 22 references indexed in Scilit:
- Safety and efficacy of liposomal iron for iron deficiency anemia in pediatric population: A systematic review and meta-analysis of randomized controlled trialsEuropean Journal of Pediatrics, 2026
- Effectiveness and Safety of Liposomal Ferric Pyrophosphate vs. Ferrous Sulfate for Intermittent Iron Prophylaxis in Children Aged 6–59 months: A Randomized Controlled TrialIndian Journal of Pediatrics, 2025
- Global prevalence of congenital heart diseases in infants: A systematic review and meta-analysisJournal of Neonatal Nursing, 2024
- Comparative Efficacy of Ferrous, Ferric and Liposomal Iron Preparations for Prophylaxis in InfantsIndian Pediatrics, 2024
- Iron deficiencyThe Lancet, 2021
- Iron-deficiency anaemia in children with congenital heart diseases at a teaching hospital in GhanaHeliyon, 2020
- Monitoring oral iron therapy in children with iron deficiency anemia: an observational, prospective, multicenter study of AIEOP patients (Associazione Italiana Emato-Oncologia Pediatrica)Annals of Hematology, 2020
- Mo1226 Comparison Between Liposomial Iron and Ferrous Sulfate in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease. A Pilot Controlled StudyGastroenterology, 2014
- Anemia in patients with heart failure and preserved systolic functionAmerican Heart Journal, 2006
- Importance of RDW value in differential diagnosis of hypochrome anemiasAmerican Journal of Hematology, 2001